BREAST CANCER

With a broadened FDA label for abemaciclib, patients high-risk breast cancer can now be categorized based only on nodal status, tumor size, and tumor grade.

Miguel Pelayo, MD, discusses what he sees as practice-changing treatments for patients with triple-negative breast cancer and how he helps patients feel confident in these new treatments.

Retrospective research shows a link behind low household income and recurrence score and survival, but there is more to uncover behind the association between socioeconomic determinants of health and tumor biology.

Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.

Treatment with (Z)-endoxifen in combination with exemestane plus goserelin in the phase 2 EVANGELINE is now underway.

With the main end points of incidence of severe neutropenia and alopecia not met in the phase 1b trial of ALRN-6924 for patients with p53-mutated breast cancer, Aileron Therapeutics has decided to end the trial.

In the phase 3 TORCHLIGHT study, survival advantages were shown with the combination of toripalimab and the chemotherapy agent nab-paclitaxel in patients with recurrent/metastatic triple-negative breast cancer treated in Chinese centers.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

A new arm of the I-SPY 2 Endocrine Optimization Platform will investigate lasofoxifene in patients with clinically high-risk ER-positive/HER2-negative breast cancer who are molecularly low-risk.

Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.

In a review of disparities among African American women with breast cancer, researchers found that the make-up of their tumor microenvironment leads to advanced diseases like triple-negative breast cancer.

In a study examining racial disparities, differences in curative intent, endocrine and/or chemotherapy, frequency and types of treatment-related adverse events, and more were seen in Non-Hispanic Black women vs Non-Hispanic White women with breast cancer.

During a Targeted Oncology case-based roundtable event, Aditya Bardia, MD, MPH, discussed the data supporting the use of sacituzumab govitecan in patients with triple-negative breast cancer.

Positive findings from the phase 3 TROPiCS-02 study have led to the FDA approval of sacituzumab govitecan-hziy for another indication.

Positive data from 2 phase 2 studies, SUMMIT and MutHER, have led to the addition of neratinib as a monotherapy or in combination to the National Comprehensive Cancer Network Guidelines for patients with breast cancer.

The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.

Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.

In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.

The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.

Starting with the PRESERVE 1 trial of patients with metastatic colorectal cancer, 5 pivotal trials evaluating trilaciclib will announce results in 2023.

During a Targeted Oncology Evolving Paradigms roundtable, Sara A. Hurvitz, MD, discussed elacestrant and other investigational agents for patients with breast cancer.

The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.

VIKTORIA-1 is a phase 3 study evaluating treatment with gedatolisib plus fulvestrant with or without palbociclib in patients with HR-positive, HER-negative breast cancer.

At a live virtual event, Priyanka Sharma, MD, discussed the treatment options for patients with metastatic breast cancer who develop triple-negative breast cancer.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

Results from the GeparOLA study show that neoadjuvant olaparib did not achieved better efficacy compared with carboplatin and paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Longer follow-up in the phase 3 STIC CTC trial substantiates that the CTC-based choice is safe in patients with metastatic breast cancer, according to investigators.

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.